Journey Medical Management
Management criteria checks 4/4
Journey Medical's CEO is Claude Maraoui, appointed in Sep 2014, has a tenure of 11.83 years. total yearly compensation is $1.67M, comprised of 35% salary and 65% bonuses, including company stock and options. directly owns 7.64% of the company’s shares, worth $14.92M. The average tenure of the management team and the board of directors is 3 years and 5 years respectively.
Key information
Claude Maraoui
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 35.03% |
| CEO tenure | 11.8yrs |
| CEO ownership | 7.6% |
| Management average tenure | 3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Narrative Update • Jun 24
DERM: Expanded Access And Parent Cash Backing Will Support Future Value
Analysts have raised their price target on Journey Medical by $1, citing updated valuations that reflect the implied value of its shares within Fortress Biotech. Supporting research keeps key assumptions unchanged, including fair value, discount rate, revenue growth, profit margin, and future P/E.Narrative Update • Jun 03
DERM: Expanded Access Progress Will Support Future Parent Group Value
Narrative Update on Journey Medical The analyst price target for Journey Medical has been adjusted from $13.25 to $13.50, as analysts factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples influenced in part by recent Street research attention on both Journey Medical and its parent Fortress Biotech. Analyst Commentary Recent Street research around Journey Medical and Fortress Biotech has given investors more context on how analysts are thinking about value, execution, and growth for Journey Medical within the broader group structure.Narrative Update • Apr 27
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.Narrative Update • Apr 12
DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.
New Narrative • Apr 10
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 28
DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
New Narrative • Mar 26
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 11
DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).Narrative Update • Feb 25
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).Narrative Update • Feb 10
DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).Narrative Update • Jan 27
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Analysis Article • Jan 14
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrative Update • Jan 12
DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.Narrative Update • Dec 27
DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).Narrative Update • Dec 12
DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.Narrative Update • Nov 28
DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.Narrative Update • Nov 14
DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.Analysis Article • Aug 15
US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Narrative Update • Aug 15
Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Analysis Article • Aug 12
Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 01
Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Narrative • Mar 30
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.Analysis Article • Mar 25
A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Analysis Article • Feb 06
Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 11
Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Analysis Article • Oct 03
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Analysis Article • Sep 14
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 06
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 11
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Analysis Article • Jan 18
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Journey Medical Corporation ( NASDAQ:DERM ) shares have retraced a considerable 33% in the last month, reversing a fair...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$10m |
| Dec 31 2025 | US$2m | US$583k | -US$11m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$9m |
| Mar 31 2025 | n/a | n/a | -US$8m |
| Dec 31 2024 | US$3m | US$567k | -US$15m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | US$843k |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$934k | US$550k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$474k | -US$30m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$41m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$464k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$2m | US$450k | US$5m |
Compensation vs Market: Claude's total compensation ($USD1.67M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Claude's compensation has been consistent with company performance over the past year.
CEO
Claude Maraoui (59 yo)
11.8yrs
Tenure
US$1,665,876
Compensation
Mr. Claude Maraoui is Founder and Director of Journey Medical Corporation since 2016 and its President and Chief Executive Officer since September 2014. Mr. Maraoui has experience in launching and commerci...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | US$460.50k | 1.23% $ 2.4m | |
| Founder | 11.8yrs | US$1.67m | 7.64% $ 14.9m | |
| CFO & Corporate Controller | 4.7yrs | US$823.67k | 0.44% $ 855.7k | |
| COO, General Counsel & Company Secretary | 1.3yrs | US$1.19m | 1.32% $ 2.6m | |
| Executive Director of Marketing | less than a year | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Senior Director of Corporate Operations | no data | no data | no data | |
| Director of Market Access | no data | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Management: DERM's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | US$460.50k | 1.23% $ 2.4m | |
| Founder | 10.5yrs | US$1.67m | 7.64% $ 14.9m | |
| Independent Director | 2yrs | US$244.20k | 0.062% $ 121.8k | |
| Independent Director | 5yrs | US$254.20k | 0.32% $ 628.3k | |
| Independent Director | 5yrs | US$244.20k | 0.55% $ 1.1m | |
| Independent Director | 5.1yrs | US$244.20k | 0.32% $ 628.3k |
5.0yrs
Average Tenure
61.5yo
Average Age
Experienced Board: DERM's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 06:52 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Journey Medical Corporation is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |